Tag Archives: Zynerba Pharmaceuticals

Up in Smoke: Zynerba Pharmaceuticals Lost More Than Half Its Value

Up in Smoke: Zynerba Pharmaceuticals Lost More Than Half Its Value

Up in Smoke: Zynerba Pharmaceuticals Lost More Than Half Its Value

Clinical-stage cannabinoid-based drug developer Zynerba Pharmaceuticals (NASDAQ:ZYNE) had been one of the strongest-performing pot stocks over the trailing year prior to the start of this past week.

5 Things You Need to Know About Marijuana Stock Zynerba Pharmaceuticals

5 Things You Need to Know About Marijuana Stock Zynerba Pharmaceuticals

There are three different general types of marijuana stocks on the market. Some are marijuana growers. Others provide supplies to marijuana growers. Then there’s the third type: the biotechs. Zynerba Pharmaceuticals belongs to the last kind of marijuana stock.

These 5 Marijuana Stocks Lost a Combined $193 Million in 2016

These 5 Marijuana Stocks Lost a Combined $193 Million in 2016

These 5 marijuana stocks lost a combined $193 Million in 2016. Though they’re some of the top performers, they’re also among the companies losing the most money on an annual basis.

5 Drug-Developing Marijuana Stocks You Need to Know

5 Drug-Developing Marijuana Stocks You Need to Know

Medical marijuana remains the safest investment route — if you’re forced to choose one — so here’s a brief rundown of the cannabinoid-based drugs working their way through clinical and preclinical trials.

Zynerba

Zynerba Pharmaceuticals Announces Pricing of Public Offering of Common Stock

DEVON, Pa., Jan. 19, 2017 /Weed Wire/ — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced the pricing of an underwritten public offering of 2.8 million shares of its common stock at a price of $18.00 per share, with expected gross proceeds to Zynerba of $50.4 million.

Vitality Biopharma: A Seriously Undervalued Cannabis Stock

Vitality Biopharma: A Seriously Undervalued Cannabis Stock

While many investors were drawn in by the myth that millions would be made by investing in the companies that purportedly planned to cultivate and sell medical and leisure based marijuana, they should have been focused on investing in companies that are intent on utilizing the plant’s cannabinoid properties, which are consistently demonstrating extraordinary benefit in treating a host of medical conditions.

Zynerba

Zynerba Pharmaceuticals to Participate in Upcoming Investor Meetings and Conferences

DEVON, Pa., June 1, 2016 /Weed Wire/ — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced that the Company will participate in various upcoming investor meetings and conferences.


Top